Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Core Insights - Rani Therapeutics has appointed two new members, Abe Bassan and Vasudev Bailey, to its Board of Directors, while Andrew Farquharson and Maulik Nanavaty have stepped down [1][2] Group 1: Board Appointments - Abe Bassan is a Partner at Samsara BioCapital, with a background in supporting therapeutics programs and experience in gene therapy [2][3] - Vasudev Bailey, Ph.D., is a General Partner at Anomaly Ventures and has a strong track record in health technology investments, along with experience in cancer detection technology [3] Group 2: Financial Developments - Rani Therapeutics has closed a private placement expected to yield gross proceeds of approximately $60.3 million, led by Samsara BioCapital [4] Group 3: Company Overview - Rani Therapeutics focuses on developing technologies for the oral delivery of biologics and drugs, with its proprietary RaniPill® capsule designed to replace injections with oral dosing [5]